| name | cancer-genomics-evidence |
| description | Synthesize public cancer genomic alterations across genes, cohorts, molecular profiles, clinical annotations, and literature. Use for somatic landscape, biomarker, resistance, or translational oncology research. |
| license | MIT |
Cancer Genomics Evidence
- Define cancer type/subtype, stage, cohort, sample/patient unit, gene/variant, alteration class, molecular profile, and clinical endpoint.
- Resolve genes with cBioPortal/NCBI/Ensembl; retrieve cohort evidence from cBioPortal and curated clinical interpretation from CIViC/ClinVar only where applicable.
- Preserve study version, assay coverage, tumor purity, sample count, denominator, alteration definition, co-occurrence method, and missing data.
- Separate prevalence, prognosis, predictive association, functional mechanism, resistance, and clinical actionability.
- Compare cohorts without pooling incompatible eligibility, ancestry, platform, treatment, or follow-up.
Return cohort-specific evidence, conflicts, bias/coverage limitations, and validation steps. Never present research output as patient-specific interpretation.
Record cohort queries and denominator decisions with $science-provenance; run $science-review before translational claims.
